Vemics Imedicor Acquires Clear Lobby Pharmacutical Communications Platform

Business Wire, Sept 18, 2008

AUSTIN, Texas -- Vemics, Inc. (Pink Sheets: VMCI) today announced it has acquired all rights to the ClearLobby pharmaceutical communications platform that will lead to the first online service creating a secure bi-directional online link between pharmaceutical companies and thousands of doctors offices around the world.

ClearLobby, upon integration into Vemics' HIPAA-compliant iMedicor portal during the fourth quarter, will enable pharmaceutical companies and their representatives to more efficiently communicate and interact with physicians. Specifically, ClearLobby will allow pharmaceutical companies to distribute timely product-specific educational resources, peer reviewed journals, white papers, clinical research studies, webinars and audio programs in an easy-to-use, portal-based service.

In addition to reducing the need for live visits by pharmaceutical salespersons to physicians' offices, ClearLobby will markedly increase the number of physicians that pharmaceutical companies can market to - as well as slash the cost of in-person marketing by as much as 80 percent per encounter, while increasing the quality of the transfer of knowledge between the parties.

ClearLobby also will allow the physician, on his or her own timetable, to instantly access updated information on new and existing products, order samples, access real-time technical assistance from a live, qualified pharmaceutical company representative, and make specific appointments with pharmaceutical sales representatives.

Vemics iMedicor CEO Fred Zolla said he believed ClearLobby would receive "strong interest" from a wide variety of pharmaceutical and medical supply companies.

"We're thrilled to have acquired this vital technology," added Mr. Zolla. "As pharmaceutical companies across the globe continue to downsize their sales forces, there is now an unprecedented need to engage physicians in a productive virtual environment capable of strengthening communications and improving sales results, while adhering to the privacy regulations (HIPAA).

"ClearLobby accomplishes this objective."

Vemics, Inc. is a leading provider of hosted, HIPAA compliant real-time medical health information exchange and professional networking portals. The Vemics iMedicor portal gives physicians, healthcare professionals, insurance companies and patients an affordable means to exchange personal health information with one another and communicate electronically. Many of iMedicor's services are free to users. IMedicor also delivers a suite of clinical solutions including the NuScribe voice driven documentation system and the "CCR Jet" Free Continuity of Care Record Exchange. Vemics is based in Austin, Texas with offices in Massachusetts, and New York. www.vemics.com, www.imedicor.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, integration of the ClearLobby technology into ours, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.